The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Tislelizumab in combination with anlotinib as first-line treatment for unresectable hepatocellular carcinoma: A single-arm, phase II clinical trial.
 
Shi-xue Laoguo
No Relationships to Disclose
 
Huasheng Huang
No Relationships to Disclose
 
Jie Zeng
No Relationships to Disclose
 
Yangfeng Jiang
No Relationships to Disclose
 
Cuizhen Liu
No Relationships to Disclose
 
Ning Mo
No Relationships to Disclose
 
GuangZhi Zhu
No Relationships to Disclose
 
Fuchao Ma
No Relationships to Disclose
 
Tao Peng
No Relationships to Disclose
 
Zhiming Zeng
No Relationships to Disclose
 
Jie Ma
No Relationships to Disclose